Naveglitazar racemate is primarily studied for its potential therapeutic applications in managing metabolic disorders, particularly type 2 diabetes. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), targeting both PPAR-alpha and PPAR-gamma. This dual activation helps improve insulin sensitivity, regulate blood glucose levels, and manage lipid metabolism, making it a candidate for addressing hyperglycemia and dyslipidemia in diabetic patients. Additionally, its effects on lipid profiles may contribute to reducing cardiovascular risks associated with metabolic syndrome. Research continues to explore its efficacy and safety in clinical settings.